TipRanks on MSN

Novo Nordisk’s new study on Ziltivekimab: A potential game-changer in heart attack treatment

Novo Nordisk ($NVO) announced an update on their ongoing clinical study. In a bid to address the persistent threat of coronary artery disease ...
TipRanks on MSN

Novo Nordisk’s CagriSema study: A potential breakthrough for chronic kidney disease and diabetes

Novo Nordisk ($NVO) announced an update on their ongoing clinical study. Study Overview: Novo Nordisk recently completed a study titled ‘Efficacy ...

2 Predictions for Novo Nordisk in 2026

Can Novo Nordisk get its comeback going in 2026? Let's discuss two things that could materialize for the company next year ...